MGMT promoter methylation was present in 33% (3/9) patients with typical carcinoid, in 22% (2/9) patients with atypical carcinoid, in 22% (8/37) patients with SCLC and in 8% (1/12) patient with LCNEC. This evidence concerns the gene MGMT and carcinoid tumor.